e-learning
resources
ERJ
2004
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
Oostenbrink J.B., Rutten-van Molken M.P.M.H., Al M.J., Van Noord J.A., Vincken W.
Source:
Eur Respir J 2004; 23: 241-249
Journal Issue:
February
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Oostenbrink J.B., Rutten-van Molken M.P.M.H., Al M.J., Van Noord J.A., Vincken W.. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241-249
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003
Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain
Source: Eur Respir J 2006; 28: Suppl. 50, 683s
Year: 2006
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 639-644
Year: 2002
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Source: Eur Respir J 2003; 21: 912
Year: 2003
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
Source: Eur Respir J 2002; 19: 209-216
Year: 2002
Tiotropium in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 205-206
Year: 2002
Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial
Source: Eur Respir J 2002; 19: 936-943
Year: 2002
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Source: Eur Respir J 2002; 19: 928-935
Year: 2002
Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Modern treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 60S-66S
Year: 2001
A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations
Source: Eur Respir J 2013; 41: 12-17
Year: 2013
Additive benefits of tiotropium in asthmatics and in patients with asthma complicated chronic obstructive pulmonary disease
Source: Eur Respir J 2007; 30: Suppl. 51, 546s
Year: 2007
Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 903-908
Year: 2001
Pulmonary rehabilitation and its effect on exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention
Year: 2005
Proactive integrated care improves quality of life in patients with COPD
Source: Eur Respir J 2009; 33: 1031-1038
Year: 2009
Efficacy of long-acting bronchodilator inhalation on postoperative pulmonary function and quality of life in lung cancer patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Actual challenges in thoracic surgery
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept